{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:07Z","timestamp":1761871267688,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clml.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T12:50:15Z","timestamp":1550926215000},"page":"e299-e306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population"],"prefix":"10.1016","volume":"19","author":[{"given":"Katherinee","family":"Morales-Chac\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianne","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo A.","family":"Acosta-Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Aguayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tuna-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.02.007_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.02.007_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3816\/CLK.2008.n.036","article-title":"Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution\u2028in Mexico City","volume":"2","author":"Aguayo","year":"2008","journal-title":"Clin Leuk"},{"key":"10.1016\/j.clml.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"suppl 3","key":"10.1016\/j.clml.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2012.0184","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am J Hematol"},{"issue":"S-4","key":"10.1016\/j.clml.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.02.007_bib12","first-page":"1505","article-title":"NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017","volume":"14","year":"2017","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2019.02.007_bib13","first-page":"1","article-title":"The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients a cross sectional study","volume":"2","author":"Savasoglu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.02.007_bib15","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-015-0128-2","article-title":"Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis","volume":"8","author":"Wang","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib23","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2016.6","article-title":"Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.02.007_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2016.231","article-title":"Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clml.2015.09.007","article-title":"Prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey","volume":"15","author":"P\u00e9rez-Jacobo","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supp 1","key":"10.1016\/j.clml.2019.02.007_bib28","first-page":"S93","article-title":"Traslocaciones complejas con t(3,9;22) podr\u00edan asociarse a toxicidad y pobre respuesta a imatinib en pacientes con leucemia mieloide cr\u00f3nica: reporte de casos","author":"Tuna-Aguilar","year":"2016","journal-title":"Revista de hematolog\u00eda"},{"volume":"Vol. 149, No. 1\u20132","year":"2016","key":"10.1016\/j.clml.2019.02.007_bib29"},{"key":"10.1016\/j.clml.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.clml.2016.04.002","article-title":"Fluorescent in situ hybridization monitoring and effect of detected early responses in the outcome of patients with chronic phase chronic myeloid leukemia: a report from a Latin American country","volume":"16","author":"Bourlon","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.02.007_bib31","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1182\/blood.V114.22.4673.4673","article-title":"Outcome of patients with Philadelphia positive chronic myeloid leukemia post imatinib failure: prognostic significance of ABL mutation and additional clonal abnormality","volume":"114","author":"Conchon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A\u00a0new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2004.03.012","article-title":"Clonal evolution in chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2019.02.007_bib36","first-page":"257b","article-title":"Non random chromosomal abnormalities in Ph-negative bone marrow cells from CML patients achieving major cytogenetic responses with STI571 (Gleevec)","volume":"98","author":"Gambacorti-Passerini","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib37","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/sj.leu.2402634","article-title":"Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8","volume":"16","author":"Andersen","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.02.007_bib38","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2003-06-1943","article-title":"Chromosomal abnormalities in Ph- cells of patients on imatinib","volume":"102","author":"McMullin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.02.007_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.leu.2402791","article-title":"Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with imatinib","volume":"17","author":"Meeus","year":"2003","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019300059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019300059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:30Z","timestamp":1761870750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019300059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S2152265019300059"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.02.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Additional Cytogenetic Abnormalities on the Clinical Behavior of Patients With Chronic Myeloid Leukemia: Report on a Latin American Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}